Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976–1995

Benhamiche, Anne-Marie; Faivre, Corinne; Minello, Anne; Clinard, François; Mitry, Emmanuel; Hillon, Patrick; Faivre, Jean

doi:10.1016/s0168-8278(98)80262-6

Cited by 52 publications

(28 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In British narrative reviews of HCC, it is commonly asserted that around 80% of tumours develop in cirrhotic livers. [71][72][73] This figure is in line with the results of a few small UK series from the 1980s, in which rates of 73-80% were reported, [74][75][76] and comparable with data from elsewhere in Europe (71-88% in France, [77][78][79][80] 75-90% in Germany, [81][82][83][84][85] 77-97% in Italy [86][87][88][89][90][91][92] and 93% in Spain 93 ). The picture may be different in North America, where similar studies suggest that the proportion of HCC patients who have cirrhosis is as low as 58% 94 to 63%.…”

Section: Aetiologysupporting

confidence: 84%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

Section: Aetiologysupporting

confidence: 84%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

show abstract

“…Trends for an increase in HCC-related deaths are looming on the horizon in many countries worldwide (table 3) [7][8][9][10][11][12], albeit the number of death per 100,000 population is still much smaller than what we now have in Japan. High prevalence rates of HCC in males Ͼ65 years reported from Scotland breathtakingly resemble what happened in Japan with its sequelae [13].…”

Section: Projection Of What Has Happened and Whatmentioning

confidence: 99%

Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future

Yamada¹

2002

Oncology

200

192

View full text Add to dashboard Cite

“…in the usa, the age-adjusted incidence rates tripled between 1975 and 2005, 2 while in France, the incidence in men increased from 7.5 per 100,000 for the period 1976-1979 to 10.2 per 100,000 for the period 1992-1995. 3 But over the past decade some favorable trends toward stabilization have been observed in France and italy, particularly in women and young adults. 4 more than 80% of cases of HCC develop in patients with pre-existing cirrhosis, which is mainly caused by hepatitis B in africa and asia, hepatitis C in Japan, southern europe and the usa, and alcohol in europe and north america.…”

Section: Introductionmentioning

confidence: 99%

Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides

Raoul

Boucher

Rolland

et al. 2010

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is becoming an important public health concern. Current therapeutic options are limited and new treatments are therefore being developed. The intra-arterial treatment chemoembolization has limited efficacy and few prospects for further progress. One particularly promising, though little used, alternative to chemoembolization is radioembolization with iodine-131 ((131)I) or rhenium-188 labeled lipiodol or yttrium-90 labeled microspheres (glass or resin beads). Three randomized studies have proven the effectiveness of (131)I-lipiodol in patients with HCC-as adjuvant therapy after surgery, compared with chemoembolization, and also in patients who have portal vein thrombosis. Microspheres enable the delivery of high-dose radiation (>200 Gy) to the tumor while sparing the neighboring hepatic tissue from overexposure. Overall, the efficacy of radioembolization has been good and toxic effects have been low. These results are comparable to those obtained with chemoembolization but further improvement can be expected by combining radioembolization with standard chemotherapy or with targeted therapies, such as anti-angiogenic drugs.

show abstract

Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976–1995

Cited by 52 publications

References 3 publications

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection in Japan: Projection to Other Countries in the Foreseeable Future

Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides

Contact Info

Product

Resources

About